Sanofi stock edges higher as vaccines and specialty drugs support earnings outlook

Sanofi (ISIN FR0000127771) is one of Europes largest pharmaceutical groups, and Sanofi stock remains closely tied to the companys earnings power in vaccines and specialty medicines. As of 30 April 2026, Sanofi reported solid full year 2025 figures, including multi billion euro revenue from key franchises according to the companys annual reporting, while its market valuation on Euronext Paris continues to reflect expectations for stable cash flows.

Revenue above EUR 40 billion

According to Sanofis published financial information for fiscal 2025, the group generated revenue of around EUR 43 billion, compared with roughly EUR 42 billion in 2024. The increase of about EUR 1 billion year on year highlights modest top line expansion supported by vaccines and immunology treatments. In its earlier full year 2024 reporting, Sanofi had disclosed revenue in the low EUR 40 billion range, so the 2025 figure marks continued growth rather than a sharp acceleration.

Net income attributable to equity holders for 2025 came in near EUR 8 billion, up from approximately EUR 7.5 billion in 2024 on the same basis. That improvement of about EUR 0.5 billion reflects a combination of incremental sales and efforts to streamline operating costs. On a per share basis, Sanofis earnings per share for 2025 reached roughly EUR 6.30, compared with about EUR 6.00 in 2024, underscoring that profitability per share is rising even as the broader pharmaceutical market wrestles with pricing pressures.

Earnings per share grow about 5 percent

The roughly EUR 6.30 earnings per share in 2025 represent an increase of around 5 percent compared with the EUR 6.00 reported for 2024. For investors tracking Sanofi stock, this mid single digit EPS growth is a useful benchmark, especially given the companys mix of mature vaccines and newer immunology drugs. The earnings progression has been supported by higher contribution from key specialty medicines and by disciplined expense management in research and development and selling, general, and administrative costs.

Sanofi has also maintained a significant investment in research, spending in the region of EUR 6 billion on R&D in 2025, similar to the level in 2024. This stable R&D commitment is central to the pipeline of new therapies and underpins the long term outlook for Sanofi stock. The balance between returning cash to shareholders through dividends and continuing to invest heavily in innovation is a recurring theme in analyst coverage, as investors gauge whether earnings growth can be sustained.

Dupixent and vaccines support growth

Sanofi generates a growing share of its revenue from the immunology drug Dupixent, which is co developed with Regeneron and has become one of the worlds leading biologic medicines for conditions such as atopic dermatitis and asthma. In 2025, Dupixent sales were estimated at more than EUR 12 billion, up from about EUR 10 billion in 2024, implying growth of roughly 20 percent year on year. That surge in Dupixent revenue has helped offset patent expiries in other portfolios and is a key pillar of Sanofis strategy.

The vaccines business is another critical contributor. Sanofi is one of the leading influenza and paediatric vaccine providers, with vaccines revenue around EUR 8 billion in 2025, compared with approximately EUR 7.5 billion in 2024. The increase reflects both higher volumes and the impact of newer formulations. Together, Dupixent and vaccines account for nearly half of group revenue, highlighting how concentrated Sanofis growth drivers have become and why any shifts in demand or pricing in these segments can quickly influence Sanofi stock.

Dividend of about EUR 3.76 per share

For fiscal 2025, Sanofi maintained its policy of returning cash to shareholders through a cash dividend. The company proposed a dividend of around EUR 3.76 per share, following a dividend of approximately EUR 3.68 per share for fiscal 2024. This small but steady increase signals confidence in cash generation and a commitment to shareholder returns. On the 2025 earnings figures, the dividend translates into a payout ratio close to 60 percent of reported earnings, a level broadly consistent with prior years.

At a share price in the mid EUR 80s, this dividend corresponds to a yield of about 4 to 5 percent, placing Sanofi stock among the higher yielding large cap pharmaceutical names in Europe. For income oriented investors, such a yield can be an important consideration, particularly at a time when interest rate expectations and bond yields are in flux. However, the dividend needs to be viewed alongside long term requirements for funding research, acquisitions, and potential restructuring.

Product focus - Dupixent and beyond

Sanofis flagship product today is Dupixent, but the company also has other important specialty medicines in oncology, neurology, and rare diseases. The commercial success of Dupixent has validated Sanofis focus on biologics and immunology and has encouraged further investment in similar pathways. Pipeline candidates in areas such as type 2 inflammation and immune mediated conditions could extend the franchise over the coming years if they meet regulatory and commercial hurdles. For each candidate, Sanofi must balance the cost of late stage trials against the potential peak sales.

In vaccines, Sanofi is investing in next generation influenza formulations and in strengthening supply capabilities for paediatric products. These investments aim to defend and grow a segment that already delivers around EUR 8 billion of annual revenue and has a relatively stable demand profile driven by global immunization programs. Any major disruption or price change in vaccines would have a direct impact on earnings, but the long term nature of contracts and health policy frameworks typically stabilizes this part of the business.

Sanofi stock valuation and market context

Sanofi is listed on Euronext Paris under the ticker SAN, and Sanofi stock is also available in the form of American depositary receipts in the United States. As of late April 2026, the companys market capitalization is around EUR 100 billion based on a share price near EUR 85. This valuation places Sanofi among the largest constituents of the CAC 40 index and makes it a core holding in many European healthcare and broad market funds. The share price level is influenced by expectations for mid single digit earnings growth, the durability of Dupixent, and the stability of the vaccines franchise.

From a long term perspective, Sanofi stock has delivered relatively modest capital gains over the past several years compared with some peers in the global pharmaceutical sector, with much of the investment case resting on dividends and defensive characteristics. The improvement in earnings from EUR 7.5 billion in 2024 to roughly EUR 8 billion in 2025 and the associated EPS uptick have provided some support, but investors also monitor regulatory developments, competition from biosimilars, and evolving pricing frameworks in key markets.